Clincosm LogoSign in Get a demo

Carcinoma, Non-Small-Cell Lung

Showing NaN - NaN of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Tumor Metastasis Trial in Worldwide (LY3537982, Pembrolizumab, Placebo)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Neoplasm Metastasis
  • Tucson, Arizona
  • +217 more
Nov 1, 2023

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Los Angeles, California
  • +83 more
Jan 31, 2023

NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +228 more
Jan 31, 2023

NSCLC Trial in Worldwide (Nivolumab, Carboplatin, Cisplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Nivolumab
  • +6 more
  • Tampa, Florida
  • +112 more
Jan 30, 2023

NSCLC Trial in Worldwide (Entrectinib, Crizotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Barretos, SP, Brazil
  • +66 more
Jan 27, 2023

NSCLC Trial in Worldwide (TAK-788)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Birmingham, Alabama
  • +56 more
Jan 23, 2023

NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Chicago, Illinois
  • +140 more
Jan 20, 2023

NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • Docetaxel
  • Beijing, China
  • +37 more
Jan 9, 2023

NSCLC Trial in Worldwide (Selpercatinib, Placebo)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Santa Monica, California
  • +206 more
Dec 27, 2022

NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +260 more
Dec 16, 2022

Stage III NSCLC RWE in Chinese Patients

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
    • BeiJing, China
    • +24 more
    Dec 14, 2022

    NSCLC Trial in China (Atezolizumab, Placebo, Bevacizumab)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Beijing City, China
    • +22 more
    Dec 7, 2022

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

    Active, not recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +39 more
    • pralsetinib (BLU-667)
    • Phoenix, Arizona
    • +65 more
    Nov 10, 2022

    Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

    Recruiting
    • Lung Neoplasms
    • +23 more
    • La Jolla, California
    • +35 more
    Oct 6, 2022

    Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)

    Recruiting
    • Lung Neoplasms
    • Carcinoma, Non-Small-Cell Lung
    • Pembrolizumab
    • +9 more
    • Mobile, Alabama
    • +194 more
    Aug 18, 2022

    Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)

    Not yet recruiting
    • Carcinoma, Non-small-Cell Lung
    • Westwood, Kansas
    • +47 more
    Aug 17, 2022

    NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Goodyear, Arizona
    • +266 more
    Aug 17, 2022

    NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Phoenix, Arizona
    • +303 more
    Aug 17, 2022

    NSCLC, Triple Negative Breast Cancer Trial in China (Datopotamab Deruxtecan (Dato-DXd))

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Triple Negative Breast Cancer
    • Datopotamab Deruxtecan (Dato-DXd)
    • Beijing, China
    • +27 more
    Aug 11, 2022

    A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +2 more
    • Beijing, Beijing, China
      Department of Respiratory and Critical Care Medicine, Peking Uni
    Aug 10, 2022

    KRAS G12C Mutant Solid Tumors, NSCLC, Carcinoma, Colorectal Trial in Worldwide (JDQ443, TNO155, tislelizumab)

    Recruiting
    • KRAS G12C Mutant Solid Tumors
    • +9 more
    • Atlanta, Georgia
    • +31 more
    Jul 7, 2022

    NSCLC Trial in China (Dabrafenib, Trametinib)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Harbin, Heilongjiang, China
    • +9 more
    Jun 13, 2022

    NSCLC Trial in Worldwide (Lorlatinib, Crizotinib)

    Active, not recruiting
    Has Results
    • Carcinoma, Non-Small-Cell Lung
    • Altamonte Springs, Florida
    • +164 more
    May 27, 2022

    NSCLC Trial in Worldwide (Atezolizumab)

    Completed
    • Carcinoma, Non-Small-Cell Lung
    • Caba, Argentina
    • +111 more
    May 25, 2022

    NSCLC Trial in China (Lorlatinib)

    Active, not recruiting
    Has Results
    • Carcinoma, Non-Small-Cell Lung
    • Hefei, Anhui, China
    • +20 more
    Sep 27, 2021